References
- Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer. 1996;4:341–350.
- Matsuura T. Hyponatremia in cancer patients. Jpn J Nephrol. 2012;54:1016–1022.
- Hamdi T, Latta S, Jallad B, et al. Cisplatin-induced renal salt wasting syndrome. South Med J. 2010;103:793–799.
- Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatremia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer. 1999;8:192–197.
- Yajima Y, Fujii M, Tokumaru Y, et al. Hyponatremia with cisplatin administration in head and neck cancer patients. Jpn J Cancer Chemother. 2010;37:2861–2865.
- Lee YK, Shin DM. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer. Korean J Intern Med. 1992;7:118–121.
- Vanhees SL, Paridaens R, Vansteenkiste JF. Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumor lysis in small-cell lung cancer. Ann Oncol. 2000;11:1061–1065.
- Nomura M, Kamata M, Kojima H, et al. Renal salt-wasting syndrome associated with docetaxel in an esophageal cancer patient. Int Canc Conf J. 2012;1:67–69.
- Cheng CY, Lin YC, Chen JS, et al. Cisplatin-induced acute hyponatremia leading to a seizure and coma. Chang Gung Med J. 2011;34:48–51.
- Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol. 2003;35:1495–1499.
- Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064–2072.